Market Access Canada
This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA
Overview
Download & View Market Access Canada as PDF for free.
More details
- Words: 7,293
- Pages: 6
Dear Colleague... After many months speaking to senior-level pharma industry executives in Canada, the biggest challenge we’re facing right now is how to bring a drug to market effectively and efficiently in this challenging environment.
Researched & Organized by eyeforpharma
World Class Speakers at a Glance
This meeting will address the key challenges you face including payor, patient and KOL engagement, relationship building, pricing & reimbursement strategy, CDR plans, pricing & drug safety and internal access management.
Daaron Dohler
You will leave the summit with a case-study driven road map for success in Canadian market access landscape – guaranteed. I look forward to meeting you and your colleagues in Toronto.
Best regards,
Vice President, Rx&D
Barbara Ouellet
Executive Director, PMPRB
Jon Gwillim VP North America eyeforpharma
PS. Sign up early and save CDN $300!
Follow me on LinkedIn www.linkedin.com/in/JonathanGwillim Group Search: Market Access for Canadian Pharma
Add Value for Stakeholders to Achieve Effective Drug Approval
Doug Grant
Vice President, Bayer
Anna Braeken
// Market Access
Executive Director
// Health Economics
Director Federal Affairs & Health Policy, Johnson & Johnson
// Federal Policy // CDR Policy
Martin Mason
// Provincial Policy
Vice President, BMS Partner, Gowlings Legal
// Regulatory Affairs
David Shum
// Commercial Management
Director Reimbursement & Health Economics, Roche
Scott Gavura
Director Provincial Drug Reimbursement Programs, Cancer Care Ontario
Principal, Market Access & Pricing Practice Lead, ZS Associates
Neelima Firth
Director, The Aequitas Group Supported by
eyeforpharma events never fail to deliver. Ian Talmage, VP Global Marketing, Bayer Healthcare
4 EASY WAYS TO REGISTER CALL
+1 866 996 1235
FAX
+1 800 814 3460
EMAIL [email protected] ONLINE www.eyeforpharma.com/MACanada
Visit www.eyeforpharma.com/MACanada
36O
PM
THE FULL SPECTRUM OF PRODUCT MANAGEMENT
Reasons to Attend
// 8 Presentations From VPs // 18 Senior Level Speakers // 12+ Hours Worth of Networking // The Premier Meeting Place for Pharma & Regulators in Canada
CDR
Barbara Ouellet PMPRB
SAVE CDN $300
Add Value for Stakeholders to Achieve Effective Drug Approval
book before 18th September
Krista Scaldwell
Ed Schoonveld
SPEAKER FACULTY: Vice President
Lesia Babiak
Gerogre Wyatt
Canada
Two Day Conference November 10–11, 2009 Radisson Admiral, Toronto, Ontario
The event will attract VPs, heads, directors and managers of: // Pricing & Reimbursement
Senior Pricing Manager, AstraZeneca
Market Access
Who Should Attend?
Head General Medicine, Bayer
Claudia Neuber
Researched & Organized by eyeforpharma
Brian O’Rourke
President & General Manager, Takeda Canada, Inc
Managing Director, Wyatt Health
Two Day Conference November 10–11, 2009 Radisson Admiral, Toronto, Ontario
Canada
Normand Laberge
We will bring together pharma industry thoughtleaders from Bayer, Abbott, BMS, Takeda, J&J and teamed them up with CDR, PMPRB and Cancer Care Ontario as well as many other key stakeholders to provide you with a platform for learning, debate and networking.
Market Access
Vice President, CDR
9 Big Pharma speakers reveal their strategies and top tips
Pharma
Pharma
Brian O’Rourke
This is your invitation to attend an innovative summit that will address the most pressing issues unique to the Canadian pharma industry.
Hear from experts on the changing governmental and provincial landscape and learn how to get the most out of your relationship on a federal level.
9 Big Pharma speakers reveal their strategies and top tips
Experts Will Discuss: // The Impact Of PMPRB On Pharma In 2010 // Effective Internal Market Access Management
Real Case Studies from 6 VPs
President and General Manager
Takeda Canada, Inc
Doug Grant Vice President Corporate Affairs
Bayer
Krista Scaldwell Vice President Market Access
BMS
Lesia Babiak Director, Federal Policy
Janssen-Ortho
eyeforpharma always deliver cutting-edge, concise conferences on a global scale, I am proud to be associated with them and see them as a key player in delivering up-to-date intelligence to the industry. Len Starnes, Head Of Digital Marketing & Sales, Bayer Schering
For the latest information visit www.eyeforpharma.com/MACanada Global Sponsor
Join eyefoprharma’s Market Access Canada LinkedIn group to be kept updated and to open up your network to the key players in the space. Search for ‘Market Access Canada’ in the Group directory.
// Better CDR Engagement // Best Practice Pricing & Reimbursement Case Studies // Federal & Provincial Government Communication
Daaron Dohler
Gold Sponsor
Supporting Sponsor
Dear Colleague... After many months speaking to senior-level pharma industry executives in Canada, the biggest challenge we’re facing right now is how to bring a drug to market effectively and efficiently in this challenging environment.
Researched & Organized by eyeforpharma
World Class Speakers at a Glance
This meeting will address the key challenges you face including payor, patient and KOL engagement, relationship building, pricing & reimbursement strategy, CDR plans, pricing & drug safety and internal access management.
Daaron Dohler
You will leave the summit with a case-study driven road map for success in Canadian market access landscape – guaranteed. I look forward to meeting you and your colleagues in Toronto.
Best regards,
Vice President, Rx&D
Barbara Ouellet
Executive Director, PMPRB
Jon Gwillim VP North America eyeforpharma
PS. Sign up early and save CDN $300!
Follow me on LinkedIn www.linkedin.com/in/JonathanGwillim Group Search: Market Access for Canadian Pharma
Add Value for Stakeholders to Achieve Effective Drug Approval
Doug Grant
Vice President, Bayer
Anna Braeken
// Market Access
Executive Director
// Health Economics
Director Federal Affairs & Health Policy, Johnson & Johnson
// Federal Policy // CDR Policy
Martin Mason
// Provincial Policy
Vice President, BMS Partner, Gowlings Legal
// Regulatory Affairs
David Shum
// Commercial Management
Director Reimbursement & Health Economics, Roche
Scott Gavura
Director Provincial Drug Reimbursement Programs, Cancer Care Ontario
Principal, Market Access & Pricing Practice Lead, ZS Associates
Neelima Firth
Director, The Aequitas Group Supported by
eyeforpharma events never fail to deliver. Ian Talmage, VP Global Marketing, Bayer Healthcare
4 EASY WAYS TO REGISTER CALL
+1 866 996 1235
FAX
+1 800 814 3460
EMAIL [email protected] ONLINE www.eyeforpharma.com/MACanada
Visit www.eyeforpharma.com/MACanada
36O
PM
THE FULL SPECTRUM OF PRODUCT MANAGEMENT
Reasons to Attend
// 8 Presentations From VPs // 18 Senior Level Speakers // 12+ Hours Worth of Networking // The Premier Meeting Place for Pharma & Regulators in Canada
CDR
Barbara Ouellet PMPRB
SAVE CDN $300
Add Value for Stakeholders to Achieve Effective Drug Approval
book before 18th September
Krista Scaldwell
Ed Schoonveld
SPEAKER FACULTY: Vice President
Lesia Babiak
Gerogre Wyatt
Canada
Two Day Conference November 10–11, 2009 Radisson Admiral, Toronto, Ontario
The event will attract VPs, heads, directors and managers of: // Pricing & Reimbursement
Senior Pricing Manager, AstraZeneca
Market Access
Who Should Attend?
Head General Medicine, Bayer
Claudia Neuber
Researched & Organized by eyeforpharma
Brian O’Rourke
President & General Manager, Takeda Canada, Inc
Managing Director, Wyatt Health
Two Day Conference November 10–11, 2009 Radisson Admiral, Toronto, Ontario
Canada
Normand Laberge
We will bring together pharma industry thoughtleaders from Bayer, Abbott, BMS, Takeda, J&J and teamed them up with CDR, PMPRB and Cancer Care Ontario as well as many other key stakeholders to provide you with a platform for learning, debate and networking.
Market Access
Vice President, CDR
9 Big Pharma speakers reveal their strategies and top tips
Pharma
Pharma
Brian O’Rourke
This is your invitation to attend an innovative summit that will address the most pressing issues unique to the Canadian pharma industry.
Hear from experts on the changing governmental and provincial landscape and learn how to get the most out of your relationship on a federal level.
9 Big Pharma speakers reveal their strategies and top tips
Experts Will Discuss: // The Impact Of PMPRB On Pharma In 2010 // Effective Internal Market Access Management
Real Case Studies from 6 VPs
President and General Manager
Takeda Canada, Inc
Doug Grant Vice President Corporate Affairs
Bayer
Krista Scaldwell Vice President Market Access
BMS
Lesia Babiak Director, Federal Policy
Janssen-Ortho
eyeforpharma always deliver cutting-edge, concise conferences on a global scale, I am proud to be associated with them and see them as a key player in delivering up-to-date intelligence to the industry. Len Starnes, Head Of Digital Marketing & Sales, Bayer Schering
For the latest information visit www.eyeforpharma.com/MACanada Global Sponsor
Join eyefoprharma’s Market Access Canada LinkedIn group to be kept updated and to open up your network to the key players in the space. Search for ‘Market Access Canada’ in the Group directory.
// Better CDR Engagement // Best Practice Pricing & Reimbursement Case Studies // Federal & Provincial Government Communication
Daaron Dohler
Gold Sponsor
Supporting Sponsor
Day 1 / Conference Agenda November 10, 2009
Day 2 / Conference Agenda November 11, 2009
ession A: Federal S Government Access Dynamics
ession C: Public Drug S Plan Approval & Government Relationships
Where do we stand? The Canadian Healthcare market in a global context
Reimbursement Programs
ession B: Provincial S Government Approval & Relationships
Explore novel approaches in a new marketplace
A Policy Update from the Common Drug Review (CDR)
// Learn how a flexible global culture can be applied and implemented for local success. // Hear an expert view of how a new start up in Canada can maximize success in a rapidly changing environment. // Best practice examples of how to adapt in today’s marketplace.
// A n update on the CDR process, timelines and activity you need to know for effective drug approval. // New initiatives introduced by the CDR. // Understand how you can solidify your submission to the CDR. // Future trends in the reimbursement environment you need to be aware of.
Daaron Dohler President, Takeda Inc
Government Relations Strategies: critical success factors for resolving regulatory, reimbursement and health policy challenges
Brian O’Rourke Vice President, Common Drug Review (CDR)
CDR: What you need to know to succeed in the Canadian Healthcare Technology environment.
// H ow to work effectively with your biggest customers: governments. // Stakeholder and government advocacy to support your regulatory, reimbursement and policy objectives. // Examples of how to implement an effective product life-cycle strategy in the evolving regulatory environment.
// S ubmissions to the CDR: What they need to see to give you the ‘Yes’. // How you can effectively manage your mainstream and biologics submissions to develop a consistent and credible plan which will enhance long-term relationships with the CDR. // How you can overcome the challenges and meet the gold standard.
Bill Dempster Director, Health & Pharma, Global Public Affairs WORKSHOP
reparing for a negotiated P agreement: ensuring a profitable outcome
// W hen should you start and who should you speak to? How to ensure your marketing is aligning the messages agreed upon in Market Access negotiations. // One goal - one strategy - one message: Best practice in setting up your launch team to effectively optimize market access knowledge. // Learn the importance of how feedback from the field force can produce an effective internal cycle of information to further improve approval processes.
Scott Gavura Director, Provincial Drug
Rx&D
Lesia Babiak Vice-Chair, Federal Policy, Johnson & Johnson
The Provincial Challenge: Examine real challenges and opportunities when getting your drug approved in the provinces and learn the crucial do’s and don’ts when in negotiations
Strategies you need to implement to get the best probability of national coverage for your drug // E stablish where the future funding and control will lie: PMPRB or Provincial authority and what this will mean for the price of your drug. // Discover strategies which dictate the provincial thinking when discussing your reimbursement. // Develop best-practice methods in listing negotiations and how value can lead to success in pricing.
// T he methods you need to know when presenting drug safety, costeffectiveness and pricing agreements between each province and what the major barriers are that you will face. // Discover what priority the provinces give for approval and what added value you need to show to win them over. // Establish a clear plan that ensures you continue to improve on dialogue and relationships to develop a win-win situation in the provinces.
Doug Grant, Vice President, Corporate Affairs, Bayer
New ways in creating value through the measurement of real world drug safety and effectiveness (RWDSE)
PA N E L D I S C U SS I O N
CALL
+1 866 996 1235
FAX
+1 800 814 3460
EMAIL [email protected] ONLINE www.eyeforpharma.com/MACanada
Expanded access using Named Patient Programs: Named Patient Programs to speed pre-launch market access
// A nalyze the current negotiated agreement environment and impacts on stakeholders. // Are negotiated agreements a fad or trend? // Looking forward: is the future for negotiated agreements sustainable?
David Shum Director Reimbursement, Health Economics Roche
Wyatt Health.
Associate Principal. ZS Associates
& Pricing Practice Lead, ZS Associates
How you should plan and implement negotiated agreements for drugs in today’s market
PA N E L D I S C U SS I O N
Private payers in the Canadian Market. What are the future challenges and opportunities.
What should marketers know about payers, market access and risk sharing?
Ed Schoonveld Principal, Market Access
Bristol Myers Squibb
// P ayers have always said that they will pay for drugs that are effective in the real world, but how do you prove effectiveness in the real world? // What perspectives and elements do you need to consider when measuring real world drug safety and effectiveness? // Learn a practical approach to measuring effectiveness that will validate desired outcomes and give payers the confidence they need to reimburse your drug.
Anna Braeken Head of General Medicine, Bayer
// O verview of global payer environment and latest trends. // How should market access impact the marketing process and clinical research? // How do you craft a value story that is compelling to payers? // What exactly is risk sharing and who is actually sharing?
Krista Scaldwell VP Market Access,
George Wyatt Managing Director,
Adam Siskind
TO REGISTER
Strategies you need to know in the product launch phase
// A n update on the New Drug Funding Program, with highlights of treatment patterns and program forecasts. // A description of CCO’s data analysis and reporting framework for systemic treatment data. // Why you should incorporate this framework to help you align best practice with public reimbursement.
Normand Laberge Vice-President,
4 EASY WAYS
ession D: Market Access S with Commercial Divisions
Use systemic treatment data to improve outcomes for patients
// H ear a descriptive and comparative analysis of the Canadian market from an IP, Pricing and reimbursement aspect and how this impacts on your geographic strategy. // Establish where the future funding and control lies, with the PMPRB or Provincial authorities? // Develop best-practice in listing negotiations and understand how transparency and value can lead to greater success in pricing.
Three Simple Steps to Register Now!
// L earn the role of Named Patient Programs and expanded access programs, what they are and why they exist. // Understand the Special Access Program of Health Canada from a pharma perspective including legal, regulatory and compliance requirements. // Review best in class recommendations and internal resource requirements to effectively manage and execute named patient programs.
Neelima Firth Director, The Aequitas Group
Visit www.eyeforpharma.com/macanada for more information
FOR PHARMA & BIOTECH COMPANIES 2 Day Conference Pass, Full event recording, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
// W hat are the main changes to the PMPRB’s 1994 Excessive Pricing Guidelines? // What are the implications of the new Guidelines? // What can be expected in the future and what measures should be taken.
2 Day Conference Pass, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
FOR SOLUTION PROVIDERS & CONSULTANTS
Patented Medicine Prices Review Board
CDN $1999
CDN $1499
CDN $1799
EARLY BIRD PRICE
(Save CDN $300 - Register by September 18th, 2009)
2 Day Conference Pass, Full event recording, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
// D iscover how to manage PMPRB scrutiny whilst developing competitive prices in the market. // Identify what market forces are proving major barriers in sustaining long-term pricing i.e Generics, Public Opinion, how you can manage these to lower the impact on your drug. // Understand what the new excessive price guidelines released this summer will mean for your products.
STANDARD PRICE
CDN $1799
CDN $2099
CDN $1599
CDN $1899
Silver Pass 2 Day Conference Pass, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
NGOs And Regulatory Bodies Pass
CDN $699
2 Day Conference Pass, Full event recording, Access to all workshops, Access to all roundtables, Lunch, Access to pre-event and post event networking.
Martin Mason Partner, Gowlings Legal
Canadian pharmaceutical pricing – where do we go from here?
CDN $400
Full event recording
// N ew PMPRB Guidelines – examine the day to day impact on Canadian pricing practice. // How does Canada fare in the global context of competitive pricing? // Looking ahead – is there a formula for success?
Mr/Mrs/Ms/Dr:
First name:
Last name:
Company:
Position/Title:
Telephone:
Fax:
Email:
Claudia Neuber Senior Pricing Manager,
Address:
AstraZeneca
// U nderstand the emerging role of the pharmacists as KOLs in the Market Access environments. // How can innovatives move away from ‘me-too’ drugs to show incremental value from the current formulary drug. // Establish new ways in creating clear and transparent safety of your drug.
CDN $1699
Gold Pass
Measuring the long-term impact of pricing regulations
Reality in 2010 and beyond
STANDARD PRICE
Silver Pass
Barbara Ouellett Executive Director,
PA N E L D I S C U SS I O N
EARLY BIRD PRICE
(Save CDN $300 - Register by September 18th, 2009)
Gold Pass
The Changing PMPRB landscape and the impact of the new Excessive Pricing Guidelines
Senior Level Pharma Speakers TBC
Strategies to succeed in a competitive market for public reimbursement
Or visit www.eyeforpharma.com/macanada to register instantly
ession E: Pricing S & Reimbursement - Key Strategies For Effective P&R Negotiations
I enclose a check/draft for: (Payable to First Conferences Ltd)
Please invoice my company:
Postcode:
Country:
Credit card number: Expiry date:
Security number:
Name on card:
Purchase Order Number: Please charge my credit card: Amex
Visa
Mastercard
Signature:
FAX THIS FORM BACK TO +1 800 814 3460 TERMS & CONDITIONS Places are transferable without any charge. Cancellations before October 9, 2009 incur an administrative charge of 25%. If you cancel your registration after October 9, 2009 we will be obliged to charge the full fee. Please note – you must notify eyeforpharma in writing of a cancellation, or we will be obliged to charge the full fee. The organisers reserve the right to make changes to the programme without notice. All prices displayed are exclusive of VAT unless otherwise stated but, VAT will be charged, where applicable, at the prevailing rate on the invoice date and the relevant details will appear on the invoice. NB: FULL PAYMENT MUST BE RECEIVED BEFORE THE EVENT
Day 1 / Conference Agenda November 10, 2009
Day 2 / Conference Agenda November 11, 2009
ession A: Federal S Government Access Dynamics
ession C: Public Drug S Plan Approval & Government Relationships
Where do we stand? The Canadian Healthcare market in a global context
Reimbursement Programs
ession B: Provincial S Government Approval & Relationships
Explore novel approaches in a new marketplace
A Policy Update from the Common Drug Review (CDR)
// Learn how a flexible global culture can be applied and implemented for local success. // Hear an expert view of how a new start up in Canada can maximize success in a rapidly changing environment. // Best practice examples of how to adapt in today’s marketplace.
// A n update on the CDR process, timelines and activity you need to know for effective drug approval. // New initiatives introduced by the CDR. // Understand how you can solidify your submission to the CDR. // Future trends in the reimbursement environment you need to be aware of.
Daaron Dohler President, Takeda Inc
Government Relations Strategies: critical success factors for resolving regulatory, reimbursement and health policy challenges
Brian O’Rourke Vice President, Common Drug Review (CDR)
CDR: What you need to know to succeed in the Canadian Healthcare Technology environment.
// H ow to work effectively with your biggest customers: governments. // Stakeholder and government advocacy to support your regulatory, reimbursement and policy objectives. // Examples of how to implement an effective product life-cycle strategy in the evolving regulatory environment.
// S ubmissions to the CDR: What they need to see to give you the ‘Yes’. // How you can effectively manage your mainstream and biologics submissions to develop a consistent and credible plan which will enhance long-term relationships with the CDR. // How you can overcome the challenges and meet the gold standard.
Bill Dempster Director, Health & Pharma, Global Public Affairs WORKSHOP
reparing for a negotiated P agreement: ensuring a profitable outcome
// W hen should you start and who should you speak to? How to ensure your marketing is aligning the messages agreed upon in Market Access negotiations. // One goal - one strategy - one message: Best practice in setting up your launch team to effectively optimize market access knowledge. // Learn the importance of how feedback from the field force can produce an effective internal cycle of information to further improve approval processes.
Scott Gavura Director, Provincial Drug
Rx&D
Lesia Babiak Vice-Chair, Federal Policy, Johnson & Johnson
The Provincial Challenge: Examine real challenges and opportunities when getting your drug approved in the provinces and learn the crucial do’s and don’ts when in negotiations
Strategies you need to implement to get the best probability of national coverage for your drug // E stablish where the future funding and control will lie: PMPRB or Provincial authority and what this will mean for the price of your drug. // Discover strategies which dictate the provincial thinking when discussing your reimbursement. // Develop best-practice methods in listing negotiations and how value can lead to success in pricing.
// T he methods you need to know when presenting drug safety, costeffectiveness and pricing agreements between each province and what the major barriers are that you will face. // Discover what priority the provinces give for approval and what added value you need to show to win them over. // Establish a clear plan that ensures you continue to improve on dialogue and relationships to develop a win-win situation in the provinces.
Doug Grant, Vice President, Corporate Affairs, Bayer
New ways in creating value through the measurement of real world drug safety and effectiveness (RWDSE)
PA N E L D I S C U SS I O N
CALL
+1 866 996 1235
FAX
+1 800 814 3460
EMAIL [email protected] ONLINE www.eyeforpharma.com/MACanada
Expanded access using Named Patient Programs: Named Patient Programs to speed pre-launch market access
// A nalyze the current negotiated agreement environment and impacts on stakeholders. // Are negotiated agreements a fad or trend? // Looking forward: is the future for negotiated agreements sustainable?
David Shum Director Reimbursement, Health Economics Roche
Wyatt Health.
Associate Principal. ZS Associates
& Pricing Practice Lead, ZS Associates
How you should plan and implement negotiated agreements for drugs in today’s market
PA N E L D I S C U SS I O N
Private payers in the Canadian Market. What are the future challenges and opportunities.
What should marketers know about payers, market access and risk sharing?
Ed Schoonveld Principal, Market Access
Bristol Myers Squibb
// P ayers have always said that they will pay for drugs that are effective in the real world, but how do you prove effectiveness in the real world? // What perspectives and elements do you need to consider when measuring real world drug safety and effectiveness? // Learn a practical approach to measuring effectiveness that will validate desired outcomes and give payers the confidence they need to reimburse your drug.
Anna Braeken Head of General Medicine, Bayer
// O verview of global payer environment and latest trends. // How should market access impact the marketing process and clinical research? // How do you craft a value story that is compelling to payers? // What exactly is risk sharing and who is actually sharing?
Krista Scaldwell VP Market Access,
George Wyatt Managing Director,
Adam Siskind
TO REGISTER
Strategies you need to know in the product launch phase
// A n update on the New Drug Funding Program, with highlights of treatment patterns and program forecasts. // A description of CCO’s data analysis and reporting framework for systemic treatment data. // Why you should incorporate this framework to help you align best practice with public reimbursement.
Normand Laberge Vice-President,
4 EASY WAYS
ession D: Market Access S with Commercial Divisions
Use systemic treatment data to improve outcomes for patients
// H ear a descriptive and comparative analysis of the Canadian market from an IP, Pricing and reimbursement aspect and how this impacts on your geographic strategy. // Establish where the future funding and control lies, with the PMPRB or Provincial authorities? // Develop best-practice in listing negotiations and understand how transparency and value can lead to greater success in pricing.
Three Simple Steps to Register Now!
// L earn the role of Named Patient Programs and expanded access programs, what they are and why they exist. // Understand the Special Access Program of Health Canada from a pharma perspective including legal, regulatory and compliance requirements. // Review best in class recommendations and internal resource requirements to effectively manage and execute named patient programs.
Neelima Firth Director, The Aequitas Group
Visit www.eyeforpharma.com/macanada for more information
FOR PHARMA & BIOTECH COMPANIES 2 Day Conference Pass, Full event recording, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
// W hat are the main changes to the PMPRB’s 1994 Excessive Pricing Guidelines? // What are the implications of the new Guidelines? // What can be expected in the future and what measures should be taken.
2 Day Conference Pass, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
FOR SOLUTION PROVIDERS & CONSULTANTS
Patented Medicine Prices Review Board
CDN $1999
CDN $1499
CDN $1799
EARLY BIRD PRICE
(Save CDN $300 - Register by September 18th, 2009)
2 Day Conference Pass, Full event recording, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
// D iscover how to manage PMPRB scrutiny whilst developing competitive prices in the market. // Identify what market forces are proving major barriers in sustaining long-term pricing i.e Generics, Public Opinion, how you can manage these to lower the impact on your drug. // Understand what the new excessive price guidelines released this summer will mean for your products.
STANDARD PRICE
CDN $1799
CDN $2099
CDN $1599
CDN $1899
Silver Pass 2 Day Conference Pass, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
NGOs And Regulatory Bodies Pass
CDN $699
2 Day Conference Pass, Full event recording, Access to all workshops, Access to all roundtables, Lunch, Access to pre-event and post event networking.
Martin Mason Partner, Gowlings Legal
Canadian pharmaceutical pricing – where do we go from here?
CDN $400
Full event recording
// N ew PMPRB Guidelines – examine the day to day impact on Canadian pricing practice. // How does Canada fare in the global context of competitive pricing? // Looking ahead – is there a formula for success?
Mr/Mrs/Ms/Dr:
First name:
Last name:
Company:
Position/Title:
Telephone:
Fax:
Email:
Claudia Neuber Senior Pricing Manager,
Address:
AstraZeneca
// U nderstand the emerging role of the pharmacists as KOLs in the Market Access environments. // How can innovatives move away from ‘me-too’ drugs to show incremental value from the current formulary drug. // Establish new ways in creating clear and transparent safety of your drug.
CDN $1699
Gold Pass
Measuring the long-term impact of pricing regulations
Reality in 2010 and beyond
STANDARD PRICE
Silver Pass
Barbara Ouellet Executive Director,
PA N E L D I S C U SS I O N
EARLY BIRD PRICE
(Save CDN $300 - Register by September 18th, 2009)
Gold Pass
The Changing PMPRB landscape and the impact of the new Excessive Pricing Guidelines
Senior Level Pharma Speakers TBC
Strategies to succeed in a competitive market for public reimbursement
Or visit www.eyeforpharma.com/macanada to register instantly
ession E: Pricing S & Reimbursement - Key Strategies For Effective P&R Negotiations
I enclose a check/draft for: (Payable to First Conferences Ltd)
Please invoice my company:
Postcode:
Country:
Credit card number: Expiry date:
Security number:
Name on card:
Purchase Order Number: Please charge my credit card: Amex
Visa
Mastercard
Signature:
FAX THIS FORM BACK TO +1 800 814 3460 TERMS & CONDITIONS Places are transferable without any charge. Cancellations before October 9, 2009 incur an administrative charge of 25%. If you cancel your registration after October 9, 2009 we will be obliged to charge the full fee. Please note – you must notify eyeforpharma in writing of a cancellation, or we will be obliged to charge the full fee. The organisers reserve the right to make changes to the programme without notice. All prices displayed are exclusive of VAT unless otherwise stated but, VAT will be charged, where applicable, at the prevailing rate on the invoice date and the relevant details will appear on the invoice. NB: FULL PAYMENT MUST BE RECEIVED BEFORE THE EVENT
Day 1 / Conference Agenda November 10, 2009
Day 2 / Conference Agenda November 11, 2009
ession A: Federal S Government Access Dynamics
ession C: Public Drug S Plan Approval & Government Relationships
Where do we stand? The Canadian Healthcare market in a global context
Reimbursement Programs
ession B: Provincial S Government Approval & Relationships
Explore novel approaches in a new marketplace
A Policy Update from the Common Drug Review (CDR)
// Learn how a flexible global culture can be applied and implemented for local success. // Hear an expert view of how a new start up in Canada can maximize success in a rapidly changing environment. // Best practice examples of how to adapt in today’s marketplace.
// A n update on the CDR process, timelines and activity you need to know for effective drug approval. // New initiatives introduced by the CDR. // Understand how you can solidify your submission to the CDR. // Future trends in the reimbursement environment you need to be aware of.
Daaron Dohler President, Takeda Inc
Government Relations Strategies: critical success factors for resolving regulatory, reimbursement and health policy challenges
Brian O’Rourke Vice President, Common Drug Review (CDR)
CDR: What you need to know to succeed in the Canadian Healthcare Technology environment.
// H ow to work effectively with your biggest customers: governments. // Stakeholder and government advocacy to support your regulatory, reimbursement and policy objectives. // Examples of how to implement an effective product life-cycle strategy in the evolving regulatory environment.
// S ubmissions to the CDR: What they need to see to give you the ‘Yes’. // How you can effectively manage your mainstream and biologics submissions to develop a consistent and credible plan which will enhance long-term relationships with the CDR. // How you can overcome the challenges and meet the gold standard.
Bill Dempster Director, Health & Pharma, Global Public Affairs WORKSHOP
reparing for a negotiated P agreement: ensuring a profitable outcome
// W hen should you start and who should you speak to? How to ensure your marketing is aligning the messages agreed upon in Market Access negotiations. // One goal - one strategy - one message: Best practice in setting up your launch team to effectively optimize market access knowledge. // Learn the importance of how feedback from the field force can produce an effective internal cycle of information to further improve approval processes.
Scott Gavura Director, Provincial Drug
Rx&D
Lesia Babiak Vice-Chair, Federal Policy, Johnson & Johnson
The Provincial Challenge: Examine real challenges and opportunities when getting your drug approved in the provinces and learn the crucial do’s and don’ts when in negotiations
Strategies you need to implement to get the best probability of national coverage for your drug // E stablish where the future funding and control will lie: PMPRB or Provincial authority and what this will mean for the price of your drug. // Discover strategies which dictate the provincial thinking when discussing your reimbursement. // Develop best-practice methods in listing negotiations and how value can lead to success in pricing.
// T he methods you need to know when presenting drug safety, costeffectiveness and pricing agreements between each province and what the major barriers are that you will face. // Discover what priority the provinces give for approval and what added value you need to show to win them over. // Establish a clear plan that ensures you continue to improve on dialogue and relationships to develop a win-win situation in the provinces.
Doug Grant, Vice President, Corporate Affairs, Bayer
New ways in creating value through the measurement of real world drug safety and effectiveness (RWDSE)
PA N E L D I S C U SS I O N
CALL
+1 866 996 1235
FAX
+1 800 814 3460
EMAIL [email protected] ONLINE www.eyeforpharma.com/MACanada
Expanded access using Named Patient Programs: Named Patient Programs to speed pre-launch market access
// A nalyze the current negotiated agreement environment and impacts on stakeholders. // Are negotiated agreements a fad or trend? // Looking forward: is the future for negotiated agreements sustainable?
David Shum Director Reimbursement, Health Economics Roche
Wyatt Health.
Associate Principal. ZS Associates
& Pricing Practice Lead, ZS Associates
How you should plan and implement negotiated agreements for drugs in today’s market
PA N E L D I S C U SS I O N
Private payers in the Canadian Market. What are the future challenges and opportunities.
What should marketers know about payers, market access and risk sharing?
Ed Schoonveld Principal, Market Access
Bristol Myers Squibb
// P ayers have always said that they will pay for drugs that are effective in the real world, but how do you prove effectiveness in the real world? // What perspectives and elements do you need to consider when measuring real world drug safety and effectiveness? // Learn a practical approach to measuring effectiveness that will validate desired outcomes and give payers the confidence they need to reimburse your drug.
Anna Braeken Head of General Medicine, Bayer
// O verview of global payer environment and latest trends. // How should market access impact the marketing process and clinical research? // How do you craft a value story that is compelling to payers? // What exactly is risk sharing and who is actually sharing?
Krista Scaldwell VP Market Access,
George Wyatt Managing Director,
Adam Siskind
TO REGISTER
Strategies you need to know in the product launch phase
// A n update on the New Drug Funding Program, with highlights of treatment patterns and program forecasts. // A description of CCO’s data analysis and reporting framework for systemic treatment data. // Why you should incorporate this framework to help you align best practice with public reimbursement.
Normand Laberge Vice-President,
4 EASY WAYS
ession D: Market Access S with Commercial Divisions
Use systemic treatment data to improve outcomes for patients
// H ear a descriptive and comparative analysis of the Canadian market from an IP, Pricing and reimbursement aspect and how this impacts on your geographic strategy. // Establish where the future funding and control lies, with the PMPRB or Provincial authorities? // Develop best-practice in listing negotiations and understand how transparency and value can lead to greater success in pricing.
Three Simple Steps to Register Now!
// L earn the role of Named Patient Programs and expanded access programs, what they are and why they exist. // Understand the Special Access Program of Health Canada from a pharma perspective including legal, regulatory and compliance requirements. // Review best in class recommendations and internal resource requirements to effectively manage and execute named patient programs.
Neelima Firth Director, The Aequitas Group
Visit www.eyeforpharma.com/macanada for more information
FOR PHARMA & BIOTECH COMPANIES 2 Day Conference Pass, Full event recording, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
// W hat are the main changes to the PMPRB’s 1994 Excessive Pricing Guidelines? // What are the implications of the new Guidelines? // What can be expected in the future and what measures should be taken.
2 Day Conference Pass, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
FOR SOLUTION PROVIDERS & CONSULTANTS
Patented Medicine Prices Review Board
CDN $1999
CDN $1499
CDN $1799
EARLY BIRD PRICE
(Save CDN $300 - Register by September 18th, 2009)
2 Day Conference Pass, Full event recording, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
// D iscover how to manage PMPRB scrutiny whilst developing competitive prices in the market. // Identify what market forces are proving major barriers in sustaining long-term pricing i.e Generics, Public Opinion, how you can manage these to lower the impact on your drug. // Understand what the new excessive price guidelines released this summer will mean for your products.
STANDARD PRICE
CDN $1799
CDN $2099
CDN $1599
CDN $1899
Silver Pass 2 Day Conference Pass, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
NGOs And Regulatory Bodies Pass
CDN $699
2 Day Conference Pass, Full event recording, Access to all workshops, Access to all roundtables, Lunch, Access to pre-event and post event networking.
Martin Mason Partner, Gowlings Legal
Canadian pharmaceutical pricing – where do we go from here?
CDN $400
Full event recording
// N ew PMPRB Guidelines – examine the day to day impact on Canadian pricing practice. // How does Canada fare in the global context of competitive pricing? // Looking ahead – is there a formula for success?
Mr/Mrs/Ms/Dr:
First name:
Last name:
Company:
Position/Title:
Telephone:
Fax:
Email:
Claudia Neuber Senior Pricing Manager,
Address:
AstraZeneca
// U nderstand the emerging role of the pharmacists as KOLs in the Market Access environments. // How can innovatives move away from ‘me-too’ drugs to show incremental value from the current formulary drug. // Establish new ways in creating clear and transparent safety of your drug.
CDN $1699
Gold Pass
Measuring the long-term impact of pricing regulations
Reality in 2010 and beyond
STANDARD PRICE
Silver Pass
Barbara Ouellett Executive Director,
PA N E L D I S C U SS I O N
EARLY BIRD PRICE
(Save CDN $300 - Register by September 18th, 2009)
Gold Pass
The Changing PMPRB landscape and the impact of the new Excessive Pricing Guidelines
Senior Level Pharma Speakers TBC
Strategies to succeed in a competitive market for public reimbursement
Or visit www.eyeforpharma.com/macanada to register instantly
ession E: Pricing S & Reimbursement - Key Strategies For Effective P&R Negotiations
I enclose a check/draft for: (Payable to First Conferences Ltd)
Please invoice my company:
Postcode:
Country:
Credit card number: Expiry date:
Security number:
Name on card:
Purchase Order Number: Please charge my credit card: Amex
Visa
Mastercard
Signature:
FAX THIS FORM BACK TO +1 800 814 3460 TERMS & CONDITIONS Places are transferable without any charge. Cancellations before October 9, 2009 incur an administrative charge of 25%. If you cancel your registration after October 9, 2009 we will be obliged to charge the full fee. Please note – you must notify eyeforpharma in writing of a cancellation, or we will be obliged to charge the full fee. The organisers reserve the right to make changes to the programme without notice. All prices displayed are exclusive of VAT unless otherwise stated but, VAT will be charged, where applicable, at the prevailing rate on the invoice date and the relevant details will appear on the invoice. NB: FULL PAYMENT MUST BE RECEIVED BEFORE THE EVENT
Dear Colleague... After many months speaking to senior-level pharma industry executives in Canada, the biggest challenge we’re facing right now is how to bring a drug to market effectively and efficiently in this challenging environment.
Researched & Organized by eyeforpharma
World Class Speakers at a Glance
This meeting will address the key challenges you face including payor, patient and KOL engagement, relationship building, pricing & reimbursement strategy, CDR plans, pricing & drug safety and internal access management.
Daaron Dohler
You will leave the summit with a case-study driven road map for success in Canadian market access landscape – guaranteed. I look forward to meeting you and your colleagues in Toronto.
Best regards,
Vice President, Rx&D
Barbra Ouellet
Executive Director, PMPRB
Jon Gwillim VP North America eyeforpharma
PS. Sign up early and save CDN $300!
Follow me on LinkedIn www.linkedin.com/in/JonathanGwillim Group Search: Market Access for Canadian Pharma
Add Value for Stakeholders to Achieve Effective Drug Approval
Doug Grant
Vice President, Bayer
Anna Braeken
// Market Access
Vice President
// Health Economics
Director Federal Affairs & Health Policy, Johnson & Johnson
// Federal Policy // CDR Policy
Martin Mason
// Provincial Policy
Vice President, BMS Partner, Gowlings Legal
// Regulatory Affairs
David Shum
// Commercial Management
Director Reimbursement & Health Economics, Roche
Scott Gavura
Director Provincial Drug Reimbursement Programs, Cancer Care Ontario
Principal, Market Access & Pricing Practice Lead, ZS Associates
Neelima Firth
Director, The Aequitas Group Supported by
eyeforpharma events never fail to deliver. Ian Talmage, VP Global Marketing, Bayer Healthcare
4 EASY WAYS TO REGISTER CALL
+1 866 996 1235
FAX
+1 800 814 3460
EMAIL [email protected] ONLINE www.eyeforpharma.com/MACanada
Visit www.eyeforpharma.com/MACanada
36O
PM
THE FULL SPECTRUM OF PRODUCT MANAGEMENT
Reasons to Attend
// 8 Presentations From VPs // 18 Senior Level Speakers // 12+ Hours Worth of Networking // The Premier Meeting Place for Pharma & Regulators in Canada
CDR
Barbara Ouellet PMPRB
SAVE CDN $300
Add Value for Stakeholders to Achieve Effective Drug Approval
book before 18th September
Krista Scaldwell
Ed Schoonveld
SPEAKER FACULTY: Vice President
Lesia Babiak
Gerogre Wyatt
Canada
Two Day Conference November 10–11, 2009 Radisson Admiral, Toronto, Ontario
The event will attract VPs, heads, directors and managers of: // Pricing & Reimbursement
Senior Pricing Manager, AstraZeneca
Market Access
Who Should Attend?
Head General Medicine, Bayer
Claudia Neuber
Researched & Organized by eyeforpharma
Brian O’Rourke
President & General Manager, Takeda Canada, Inc
Managing Director, Wyatt Health
Two Day Conference November 10–11, 2009 Radisson Admiral, Toronto, Ontario
Canada
Normand Laberge
We will bring together pharma industry thoughtleaders from Bayer, Abbott, BMS, Takeda, J&J and teamed them up with CDR, PMPRB and Cancer Care Ontario as well as many other key stakeholders to provide you with a platform for learning, debate and networking.
Market Access
Vice President, CDR
9 Big Pharma speakers reveal their strategies and top tips
Pharma
Pharma
Brian O’Rourke
This is your invitation to attend an innovative summit that will address the most pressing issues unique to the Canadian pharma industry.
Hear from experts on the changing governmental and provincial landscape and learn how to get the most out of your relationship on a federal level.
9 Big Pharma speakers reveal their strategies and top tips
Experts Will Discuss: // The Impact Of PMPRB On Pharma In 2010 // Effective Internal Market Access Management
Real Case Studies from 6 VPs
President and General Manager
Takeda Canada, Inc
Doug Grant Vice President Corporate Affairs
Bayer
Krista Scaldwell Vice President Market Access
BMS
Lesia Babiak Director, Federal Policy
Janssen-Ortho
eyeforpharma always deliver cutting-edge, concise conferences on a global scale, I am proud to be associated with them and see them as a key player in delivering up-to-date intelligence to the industry. Len Starnes, Head Of Digital Marketing & Sales, Bayer Schering
For the latest information visit www.eyeforpharma.com/MACanada Global Sponsor
Join eyefoprharma’s Market Access Canada LinkedIn group to be kept updated and to open up your network to the key players in the space. Search for ‘Market Access Canada’ in the Group directory.
// Better CDR Engagement // Best Practice Pricing & Reimbursement Case Studies // Federal & Provincial Government Communication
Daaron Dohler
Gold Sponsor
Supporting Sponsor
Researched & Organized by eyeforpharma
World Class Speakers at a Glance
This meeting will address the key challenges you face including payor, patient and KOL engagement, relationship building, pricing & reimbursement strategy, CDR plans, pricing & drug safety and internal access management.
Daaron Dohler
You will leave the summit with a case-study driven road map for success in Canadian market access landscape – guaranteed. I look forward to meeting you and your colleagues in Toronto.
Best regards,
Vice President, Rx&D
Barbara Ouellet
Executive Director, PMPRB
Jon Gwillim VP North America eyeforpharma
PS. Sign up early and save CDN $300!
Follow me on LinkedIn www.linkedin.com/in/JonathanGwillim Group Search: Market Access for Canadian Pharma
Add Value for Stakeholders to Achieve Effective Drug Approval
Doug Grant
Vice President, Bayer
Anna Braeken
// Market Access
Executive Director
// Health Economics
Director Federal Affairs & Health Policy, Johnson & Johnson
// Federal Policy // CDR Policy
Martin Mason
// Provincial Policy
Vice President, BMS Partner, Gowlings Legal
// Regulatory Affairs
David Shum
// Commercial Management
Director Reimbursement & Health Economics, Roche
Scott Gavura
Director Provincial Drug Reimbursement Programs, Cancer Care Ontario
Principal, Market Access & Pricing Practice Lead, ZS Associates
Neelima Firth
Director, The Aequitas Group Supported by
eyeforpharma events never fail to deliver. Ian Talmage, VP Global Marketing, Bayer Healthcare
4 EASY WAYS TO REGISTER CALL
+1 866 996 1235
FAX
+1 800 814 3460
EMAIL [email protected] ONLINE www.eyeforpharma.com/MACanada
Visit www.eyeforpharma.com/MACanada
36O
PM
THE FULL SPECTRUM OF PRODUCT MANAGEMENT
Reasons to Attend
// 8 Presentations From VPs // 18 Senior Level Speakers // 12+ Hours Worth of Networking // The Premier Meeting Place for Pharma & Regulators in Canada
CDR
Barbara Ouellet PMPRB
SAVE CDN $300
Add Value for Stakeholders to Achieve Effective Drug Approval
book before 18th September
Krista Scaldwell
Ed Schoonveld
SPEAKER FACULTY: Vice President
Lesia Babiak
Gerogre Wyatt
Canada
Two Day Conference November 10–11, 2009 Radisson Admiral, Toronto, Ontario
The event will attract VPs, heads, directors and managers of: // Pricing & Reimbursement
Senior Pricing Manager, AstraZeneca
Market Access
Who Should Attend?
Head General Medicine, Bayer
Claudia Neuber
Researched & Organized by eyeforpharma
Brian O’Rourke
President & General Manager, Takeda Canada, Inc
Managing Director, Wyatt Health
Two Day Conference November 10–11, 2009 Radisson Admiral, Toronto, Ontario
Canada
Normand Laberge
We will bring together pharma industry thoughtleaders from Bayer, Abbott, BMS, Takeda, J&J and teamed them up with CDR, PMPRB and Cancer Care Ontario as well as many other key stakeholders to provide you with a platform for learning, debate and networking.
Market Access
Vice President, CDR
9 Big Pharma speakers reveal their strategies and top tips
Pharma
Pharma
Brian O’Rourke
This is your invitation to attend an innovative summit that will address the most pressing issues unique to the Canadian pharma industry.
Hear from experts on the changing governmental and provincial landscape and learn how to get the most out of your relationship on a federal level.
9 Big Pharma speakers reveal their strategies and top tips
Experts Will Discuss: // The Impact Of PMPRB On Pharma In 2010 // Effective Internal Market Access Management
Real Case Studies from 6 VPs
President and General Manager
Takeda Canada, Inc
Doug Grant Vice President Corporate Affairs
Bayer
Krista Scaldwell Vice President Market Access
BMS
Lesia Babiak Director, Federal Policy
Janssen-Ortho
eyeforpharma always deliver cutting-edge, concise conferences on a global scale, I am proud to be associated with them and see them as a key player in delivering up-to-date intelligence to the industry. Len Starnes, Head Of Digital Marketing & Sales, Bayer Schering
For the latest information visit www.eyeforpharma.com/MACanada Global Sponsor
Join eyefoprharma’s Market Access Canada LinkedIn group to be kept updated and to open up your network to the key players in the space. Search for ‘Market Access Canada’ in the Group directory.
// Better CDR Engagement // Best Practice Pricing & Reimbursement Case Studies // Federal & Provincial Government Communication
Daaron Dohler
Gold Sponsor
Supporting Sponsor
Dear Colleague... After many months speaking to senior-level pharma industry executives in Canada, the biggest challenge we’re facing right now is how to bring a drug to market effectively and efficiently in this challenging environment.
Researched & Organized by eyeforpharma
World Class Speakers at a Glance
This meeting will address the key challenges you face including payor, patient and KOL engagement, relationship building, pricing & reimbursement strategy, CDR plans, pricing & drug safety and internal access management.
Daaron Dohler
You will leave the summit with a case-study driven road map for success in Canadian market access landscape – guaranteed. I look forward to meeting you and your colleagues in Toronto.
Best regards,
Vice President, Rx&D
Barbara Ouellet
Executive Director, PMPRB
Jon Gwillim VP North America eyeforpharma
PS. Sign up early and save CDN $300!
Follow me on LinkedIn www.linkedin.com/in/JonathanGwillim Group Search: Market Access for Canadian Pharma
Add Value for Stakeholders to Achieve Effective Drug Approval
Doug Grant
Vice President, Bayer
Anna Braeken
// Market Access
Executive Director
// Health Economics
Director Federal Affairs & Health Policy, Johnson & Johnson
// Federal Policy // CDR Policy
Martin Mason
// Provincial Policy
Vice President, BMS Partner, Gowlings Legal
// Regulatory Affairs
David Shum
// Commercial Management
Director Reimbursement & Health Economics, Roche
Scott Gavura
Director Provincial Drug Reimbursement Programs, Cancer Care Ontario
Principal, Market Access & Pricing Practice Lead, ZS Associates
Neelima Firth
Director, The Aequitas Group Supported by
eyeforpharma events never fail to deliver. Ian Talmage, VP Global Marketing, Bayer Healthcare
4 EASY WAYS TO REGISTER CALL
+1 866 996 1235
FAX
+1 800 814 3460
EMAIL [email protected] ONLINE www.eyeforpharma.com/MACanada
Visit www.eyeforpharma.com/MACanada
36O
PM
THE FULL SPECTRUM OF PRODUCT MANAGEMENT
Reasons to Attend
// 8 Presentations From VPs // 18 Senior Level Speakers // 12+ Hours Worth of Networking // The Premier Meeting Place for Pharma & Regulators in Canada
CDR
Barbara Ouellet PMPRB
SAVE CDN $300
Add Value for Stakeholders to Achieve Effective Drug Approval
book before 18th September
Krista Scaldwell
Ed Schoonveld
SPEAKER FACULTY: Vice President
Lesia Babiak
Gerogre Wyatt
Canada
Two Day Conference November 10–11, 2009 Radisson Admiral, Toronto, Ontario
The event will attract VPs, heads, directors and managers of: // Pricing & Reimbursement
Senior Pricing Manager, AstraZeneca
Market Access
Who Should Attend?
Head General Medicine, Bayer
Claudia Neuber
Researched & Organized by eyeforpharma
Brian O’Rourke
President & General Manager, Takeda Canada, Inc
Managing Director, Wyatt Health
Two Day Conference November 10–11, 2009 Radisson Admiral, Toronto, Ontario
Canada
Normand Laberge
We will bring together pharma industry thoughtleaders from Bayer, Abbott, BMS, Takeda, J&J and teamed them up with CDR, PMPRB and Cancer Care Ontario as well as many other key stakeholders to provide you with a platform for learning, debate and networking.
Market Access
Vice President, CDR
9 Big Pharma speakers reveal their strategies and top tips
Pharma
Pharma
Brian O’Rourke
This is your invitation to attend an innovative summit that will address the most pressing issues unique to the Canadian pharma industry.
Hear from experts on the changing governmental and provincial landscape and learn how to get the most out of your relationship on a federal level.
9 Big Pharma speakers reveal their strategies and top tips
Experts Will Discuss: // The Impact Of PMPRB On Pharma In 2010 // Effective Internal Market Access Management
Real Case Studies from 6 VPs
President and General Manager
Takeda Canada, Inc
Doug Grant Vice President Corporate Affairs
Bayer
Krista Scaldwell Vice President Market Access
BMS
Lesia Babiak Director, Federal Policy
Janssen-Ortho
eyeforpharma always deliver cutting-edge, concise conferences on a global scale, I am proud to be associated with them and see them as a key player in delivering up-to-date intelligence to the industry. Len Starnes, Head Of Digital Marketing & Sales, Bayer Schering
For the latest information visit www.eyeforpharma.com/MACanada Global Sponsor
Join eyefoprharma’s Market Access Canada LinkedIn group to be kept updated and to open up your network to the key players in the space. Search for ‘Market Access Canada’ in the Group directory.
// Better CDR Engagement // Best Practice Pricing & Reimbursement Case Studies // Federal & Provincial Government Communication
Daaron Dohler
Gold Sponsor
Supporting Sponsor
Day 1 / Conference Agenda November 10, 2009
Day 2 / Conference Agenda November 11, 2009
ession A: Federal S Government Access Dynamics
ession C: Public Drug S Plan Approval & Government Relationships
Where do we stand? The Canadian Healthcare market in a global context
Reimbursement Programs
ession B: Provincial S Government Approval & Relationships
Explore novel approaches in a new marketplace
A Policy Update from the Common Drug Review (CDR)
// Learn how a flexible global culture can be applied and implemented for local success. // Hear an expert view of how a new start up in Canada can maximize success in a rapidly changing environment. // Best practice examples of how to adapt in today’s marketplace.
// A n update on the CDR process, timelines and activity you need to know for effective drug approval. // New initiatives introduced by the CDR. // Understand how you can solidify your submission to the CDR. // Future trends in the reimbursement environment you need to be aware of.
Daaron Dohler President, Takeda Inc
Government Relations Strategies: critical success factors for resolving regulatory, reimbursement and health policy challenges
Brian O’Rourke Vice President, Common Drug Review (CDR)
CDR: What you need to know to succeed in the Canadian Healthcare Technology environment.
// H ow to work effectively with your biggest customers: governments. // Stakeholder and government advocacy to support your regulatory, reimbursement and policy objectives. // Examples of how to implement an effective product life-cycle strategy in the evolving regulatory environment.
// S ubmissions to the CDR: What they need to see to give you the ‘Yes’. // How you can effectively manage your mainstream and biologics submissions to develop a consistent and credible plan which will enhance long-term relationships with the CDR. // How you can overcome the challenges and meet the gold standard.
Bill Dempster Director, Health & Pharma, Global Public Affairs WORKSHOP
reparing for a negotiated P agreement: ensuring a profitable outcome
// W hen should you start and who should you speak to? How to ensure your marketing is aligning the messages agreed upon in Market Access negotiations. // One goal - one strategy - one message: Best practice in setting up your launch team to effectively optimize market access knowledge. // Learn the importance of how feedback from the field force can produce an effective internal cycle of information to further improve approval processes.
Scott Gavura Director, Provincial Drug
Rx&D
Lesia Babiak Vice-Chair, Federal Policy, Johnson & Johnson
The Provincial Challenge: Examine real challenges and opportunities when getting your drug approved in the provinces and learn the crucial do’s and don’ts when in negotiations
Strategies you need to implement to get the best probability of national coverage for your drug // E stablish where the future funding and control will lie: PMPRB or Provincial authority and what this will mean for the price of your drug. // Discover strategies which dictate the provincial thinking when discussing your reimbursement. // Develop best-practice methods in listing negotiations and how value can lead to success in pricing.
// T he methods you need to know when presenting drug safety, costeffectiveness and pricing agreements between each province and what the major barriers are that you will face. // Discover what priority the provinces give for approval and what added value you need to show to win them over. // Establish a clear plan that ensures you continue to improve on dialogue and relationships to develop a win-win situation in the provinces.
Doug Grant, Vice President, Corporate Affairs, Bayer
New ways in creating value through the measurement of real world drug safety and effectiveness (RWDSE)
PA N E L D I S C U SS I O N
CALL
+1 866 996 1235
FAX
+1 800 814 3460
EMAIL [email protected] ONLINE www.eyeforpharma.com/MACanada
Expanded access using Named Patient Programs: Named Patient Programs to speed pre-launch market access
// A nalyze the current negotiated agreement environment and impacts on stakeholders. // Are negotiated agreements a fad or trend? // Looking forward: is the future for negotiated agreements sustainable?
David Shum Director Reimbursement, Health Economics Roche
Wyatt Health.
Associate Principal. ZS Associates
& Pricing Practice Lead, ZS Associates
How you should plan and implement negotiated agreements for drugs in today’s market
PA N E L D I S C U SS I O N
Private payers in the Canadian Market. What are the future challenges and opportunities.
What should marketers know about payers, market access and risk sharing?
Ed Schoonveld Principal, Market Access
Bristol Myers Squibb
// P ayers have always said that they will pay for drugs that are effective in the real world, but how do you prove effectiveness in the real world? // What perspectives and elements do you need to consider when measuring real world drug safety and effectiveness? // Learn a practical approach to measuring effectiveness that will validate desired outcomes and give payers the confidence they need to reimburse your drug.
Anna Braeken Head of General Medicine, Bayer
// O verview of global payer environment and latest trends. // How should market access impact the marketing process and clinical research? // How do you craft a value story that is compelling to payers? // What exactly is risk sharing and who is actually sharing?
Krista Scaldwell VP Market Access,
George Wyatt Managing Director,
Adam Siskind
TO REGISTER
Strategies you need to know in the product launch phase
// A n update on the New Drug Funding Program, with highlights of treatment patterns and program forecasts. // A description of CCO’s data analysis and reporting framework for systemic treatment data. // Why you should incorporate this framework to help you align best practice with public reimbursement.
Normand Laberge Vice-President,
4 EASY WAYS
ession D: Market Access S with Commercial Divisions
Use systemic treatment data to improve outcomes for patients
// H ear a descriptive and comparative analysis of the Canadian market from an IP, Pricing and reimbursement aspect and how this impacts on your geographic strategy. // Establish where the future funding and control lies, with the PMPRB or Provincial authorities? // Develop best-practice in listing negotiations and understand how transparency and value can lead to greater success in pricing.
Three Simple Steps to Register Now!
// L earn the role of Named Patient Programs and expanded access programs, what they are and why they exist. // Understand the Special Access Program of Health Canada from a pharma perspective including legal, regulatory and compliance requirements. // Review best in class recommendations and internal resource requirements to effectively manage and execute named patient programs.
Neelima Firth Director, The Aequitas Group
Visit www.eyeforpharma.com/macanada for more information
FOR PHARMA & BIOTECH COMPANIES 2 Day Conference Pass, Full event recording, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
// W hat are the main changes to the PMPRB’s 1994 Excessive Pricing Guidelines? // What are the implications of the new Guidelines? // What can be expected in the future and what measures should be taken.
2 Day Conference Pass, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
FOR SOLUTION PROVIDERS & CONSULTANTS
Patented Medicine Prices Review Board
CDN $1999
CDN $1499
CDN $1799
EARLY BIRD PRICE
(Save CDN $300 - Register by September 18th, 2009)
2 Day Conference Pass, Full event recording, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
// D iscover how to manage PMPRB scrutiny whilst developing competitive prices in the market. // Identify what market forces are proving major barriers in sustaining long-term pricing i.e Generics, Public Opinion, how you can manage these to lower the impact on your drug. // Understand what the new excessive price guidelines released this summer will mean for your products.
STANDARD PRICE
CDN $1799
CDN $2099
CDN $1599
CDN $1899
Silver Pass 2 Day Conference Pass, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
NGOs And Regulatory Bodies Pass
CDN $699
2 Day Conference Pass, Full event recording, Access to all workshops, Access to all roundtables, Lunch, Access to pre-event and post event networking.
Martin Mason Partner, Gowlings Legal
Canadian pharmaceutical pricing – where do we go from here?
CDN $400
Full event recording
// N ew PMPRB Guidelines – examine the day to day impact on Canadian pricing practice. // How does Canada fare in the global context of competitive pricing? // Looking ahead – is there a formula for success?
Mr/Mrs/Ms/Dr:
First name:
Last name:
Company:
Position/Title:
Telephone:
Fax:
Email:
Claudia Neuber Senior Pricing Manager,
Address:
AstraZeneca
// U nderstand the emerging role of the pharmacists as KOLs in the Market Access environments. // How can innovatives move away from ‘me-too’ drugs to show incremental value from the current formulary drug. // Establish new ways in creating clear and transparent safety of your drug.
CDN $1699
Gold Pass
Measuring the long-term impact of pricing regulations
Reality in 2010 and beyond
STANDARD PRICE
Silver Pass
Barbara Ouellett Executive Director,
PA N E L D I S C U SS I O N
EARLY BIRD PRICE
(Save CDN $300 - Register by September 18th, 2009)
Gold Pass
The Changing PMPRB landscape and the impact of the new Excessive Pricing Guidelines
Senior Level Pharma Speakers TBC
Strategies to succeed in a competitive market for public reimbursement
Or visit www.eyeforpharma.com/macanada to register instantly
ession E: Pricing S & Reimbursement - Key Strategies For Effective P&R Negotiations
I enclose a check/draft for: (Payable to First Conferences Ltd)
Please invoice my company:
Postcode:
Country:
Credit card number: Expiry date:
Security number:
Name on card:
Purchase Order Number: Please charge my credit card: Amex
Visa
Mastercard
Signature:
FAX THIS FORM BACK TO +1 800 814 3460 TERMS & CONDITIONS Places are transferable without any charge. Cancellations before October 9, 2009 incur an administrative charge of 25%. If you cancel your registration after October 9, 2009 we will be obliged to charge the full fee. Please note – you must notify eyeforpharma in writing of a cancellation, or we will be obliged to charge the full fee. The organisers reserve the right to make changes to the programme without notice. All prices displayed are exclusive of VAT unless otherwise stated but, VAT will be charged, where applicable, at the prevailing rate on the invoice date and the relevant details will appear on the invoice. NB: FULL PAYMENT MUST BE RECEIVED BEFORE THE EVENT
Day 1 / Conference Agenda November 10, 2009
Day 2 / Conference Agenda November 11, 2009
ession A: Federal S Government Access Dynamics
ession C: Public Drug S Plan Approval & Government Relationships
Where do we stand? The Canadian Healthcare market in a global context
Reimbursement Programs
ession B: Provincial S Government Approval & Relationships
Explore novel approaches in a new marketplace
A Policy Update from the Common Drug Review (CDR)
// Learn how a flexible global culture can be applied and implemented for local success. // Hear an expert view of how a new start up in Canada can maximize success in a rapidly changing environment. // Best practice examples of how to adapt in today’s marketplace.
// A n update on the CDR process, timelines and activity you need to know for effective drug approval. // New initiatives introduced by the CDR. // Understand how you can solidify your submission to the CDR. // Future trends in the reimbursement environment you need to be aware of.
Daaron Dohler President, Takeda Inc
Government Relations Strategies: critical success factors for resolving regulatory, reimbursement and health policy challenges
Brian O’Rourke Vice President, Common Drug Review (CDR)
CDR: What you need to know to succeed in the Canadian Healthcare Technology environment.
// H ow to work effectively with your biggest customers: governments. // Stakeholder and government advocacy to support your regulatory, reimbursement and policy objectives. // Examples of how to implement an effective product life-cycle strategy in the evolving regulatory environment.
// S ubmissions to the CDR: What they need to see to give you the ‘Yes’. // How you can effectively manage your mainstream and biologics submissions to develop a consistent and credible plan which will enhance long-term relationships with the CDR. // How you can overcome the challenges and meet the gold standard.
Bill Dempster Director, Health & Pharma, Global Public Affairs WORKSHOP
reparing for a negotiated P agreement: ensuring a profitable outcome
// W hen should you start and who should you speak to? How to ensure your marketing is aligning the messages agreed upon in Market Access negotiations. // One goal - one strategy - one message: Best practice in setting up your launch team to effectively optimize market access knowledge. // Learn the importance of how feedback from the field force can produce an effective internal cycle of information to further improve approval processes.
Scott Gavura Director, Provincial Drug
Rx&D
Lesia Babiak Vice-Chair, Federal Policy, Johnson & Johnson
The Provincial Challenge: Examine real challenges and opportunities when getting your drug approved in the provinces and learn the crucial do’s and don’ts when in negotiations
Strategies you need to implement to get the best probability of national coverage for your drug // E stablish where the future funding and control will lie: PMPRB or Provincial authority and what this will mean for the price of your drug. // Discover strategies which dictate the provincial thinking when discussing your reimbursement. // Develop best-practice methods in listing negotiations and how value can lead to success in pricing.
// T he methods you need to know when presenting drug safety, costeffectiveness and pricing agreements between each province and what the major barriers are that you will face. // Discover what priority the provinces give for approval and what added value you need to show to win them over. // Establish a clear plan that ensures you continue to improve on dialogue and relationships to develop a win-win situation in the provinces.
Doug Grant, Vice President, Corporate Affairs, Bayer
New ways in creating value through the measurement of real world drug safety and effectiveness (RWDSE)
PA N E L D I S C U SS I O N
CALL
+1 866 996 1235
FAX
+1 800 814 3460
EMAIL [email protected] ONLINE www.eyeforpharma.com/MACanada
Expanded access using Named Patient Programs: Named Patient Programs to speed pre-launch market access
// A nalyze the current negotiated agreement environment and impacts on stakeholders. // Are negotiated agreements a fad or trend? // Looking forward: is the future for negotiated agreements sustainable?
David Shum Director Reimbursement, Health Economics Roche
Wyatt Health.
Associate Principal. ZS Associates
& Pricing Practice Lead, ZS Associates
How you should plan and implement negotiated agreements for drugs in today’s market
PA N E L D I S C U SS I O N
Private payers in the Canadian Market. What are the future challenges and opportunities.
What should marketers know about payers, market access and risk sharing?
Ed Schoonveld Principal, Market Access
Bristol Myers Squibb
// P ayers have always said that they will pay for drugs that are effective in the real world, but how do you prove effectiveness in the real world? // What perspectives and elements do you need to consider when measuring real world drug safety and effectiveness? // Learn a practical approach to measuring effectiveness that will validate desired outcomes and give payers the confidence they need to reimburse your drug.
Anna Braeken Head of General Medicine, Bayer
// O verview of global payer environment and latest trends. // How should market access impact the marketing process and clinical research? // How do you craft a value story that is compelling to payers? // What exactly is risk sharing and who is actually sharing?
Krista Scaldwell VP Market Access,
George Wyatt Managing Director,
Adam Siskind
TO REGISTER
Strategies you need to know in the product launch phase
// A n update on the New Drug Funding Program, with highlights of treatment patterns and program forecasts. // A description of CCO’s data analysis and reporting framework for systemic treatment data. // Why you should incorporate this framework to help you align best practice with public reimbursement.
Normand Laberge Vice-President,
4 EASY WAYS
ession D: Market Access S with Commercial Divisions
Use systemic treatment data to improve outcomes for patients
// H ear a descriptive and comparative analysis of the Canadian market from an IP, Pricing and reimbursement aspect and how this impacts on your geographic strategy. // Establish where the future funding and control lies, with the PMPRB or Provincial authorities? // Develop best-practice in listing negotiations and understand how transparency and value can lead to greater success in pricing.
Three Simple Steps to Register Now!
// L earn the role of Named Patient Programs and expanded access programs, what they are and why they exist. // Understand the Special Access Program of Health Canada from a pharma perspective including legal, regulatory and compliance requirements. // Review best in class recommendations and internal resource requirements to effectively manage and execute named patient programs.
Neelima Firth Director, The Aequitas Group
Visit www.eyeforpharma.com/macanada for more information
FOR PHARMA & BIOTECH COMPANIES 2 Day Conference Pass, Full event recording, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
// W hat are the main changes to the PMPRB’s 1994 Excessive Pricing Guidelines? // What are the implications of the new Guidelines? // What can be expected in the future and what measures should be taken.
2 Day Conference Pass, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
FOR SOLUTION PROVIDERS & CONSULTANTS
Patented Medicine Prices Review Board
CDN $1999
CDN $1499
CDN $1799
EARLY BIRD PRICE
(Save CDN $300 - Register by September 18th, 2009)
2 Day Conference Pass, Full event recording, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
// D iscover how to manage PMPRB scrutiny whilst developing competitive prices in the market. // Identify what market forces are proving major barriers in sustaining long-term pricing i.e Generics, Public Opinion, how you can manage these to lower the impact on your drug. // Understand what the new excessive price guidelines released this summer will mean for your products.
STANDARD PRICE
CDN $1799
CDN $2099
CDN $1599
CDN $1899
Silver Pass 2 Day Conference Pass, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
NGOs And Regulatory Bodies Pass
CDN $699
2 Day Conference Pass, Full event recording, Access to all workshops, Access to all roundtables, Lunch, Access to pre-event and post event networking.
Martin Mason Partner, Gowlings Legal
Canadian pharmaceutical pricing – where do we go from here?
CDN $400
Full event recording
// N ew PMPRB Guidelines – examine the day to day impact on Canadian pricing practice. // How does Canada fare in the global context of competitive pricing? // Looking ahead – is there a formula for success?
Mr/Mrs/Ms/Dr:
First name:
Last name:
Company:
Position/Title:
Telephone:
Fax:
Email:
Claudia Neuber Senior Pricing Manager,
Address:
AstraZeneca
// U nderstand the emerging role of the pharmacists as KOLs in the Market Access environments. // How can innovatives move away from ‘me-too’ drugs to show incremental value from the current formulary drug. // Establish new ways in creating clear and transparent safety of your drug.
CDN $1699
Gold Pass
Measuring the long-term impact of pricing regulations
Reality in 2010 and beyond
STANDARD PRICE
Silver Pass
Barbara Ouellet Executive Director,
PA N E L D I S C U SS I O N
EARLY BIRD PRICE
(Save CDN $300 - Register by September 18th, 2009)
Gold Pass
The Changing PMPRB landscape and the impact of the new Excessive Pricing Guidelines
Senior Level Pharma Speakers TBC
Strategies to succeed in a competitive market for public reimbursement
Or visit www.eyeforpharma.com/macanada to register instantly
ession E: Pricing S & Reimbursement - Key Strategies For Effective P&R Negotiations
I enclose a check/draft for: (Payable to First Conferences Ltd)
Please invoice my company:
Postcode:
Country:
Credit card number: Expiry date:
Security number:
Name on card:
Purchase Order Number: Please charge my credit card: Amex
Visa
Mastercard
Signature:
FAX THIS FORM BACK TO +1 800 814 3460 TERMS & CONDITIONS Places are transferable without any charge. Cancellations before October 9, 2009 incur an administrative charge of 25%. If you cancel your registration after October 9, 2009 we will be obliged to charge the full fee. Please note – you must notify eyeforpharma in writing of a cancellation, or we will be obliged to charge the full fee. The organisers reserve the right to make changes to the programme without notice. All prices displayed are exclusive of VAT unless otherwise stated but, VAT will be charged, where applicable, at the prevailing rate on the invoice date and the relevant details will appear on the invoice. NB: FULL PAYMENT MUST BE RECEIVED BEFORE THE EVENT
Day 1 / Conference Agenda November 10, 2009
Day 2 / Conference Agenda November 11, 2009
ession A: Federal S Government Access Dynamics
ession C: Public Drug S Plan Approval & Government Relationships
Where do we stand? The Canadian Healthcare market in a global context
Reimbursement Programs
ession B: Provincial S Government Approval & Relationships
Explore novel approaches in a new marketplace
A Policy Update from the Common Drug Review (CDR)
// Learn how a flexible global culture can be applied and implemented for local success. // Hear an expert view of how a new start up in Canada can maximize success in a rapidly changing environment. // Best practice examples of how to adapt in today’s marketplace.
// A n update on the CDR process, timelines and activity you need to know for effective drug approval. // New initiatives introduced by the CDR. // Understand how you can solidify your submission to the CDR. // Future trends in the reimbursement environment you need to be aware of.
Daaron Dohler President, Takeda Inc
Government Relations Strategies: critical success factors for resolving regulatory, reimbursement and health policy challenges
Brian O’Rourke Vice President, Common Drug Review (CDR)
CDR: What you need to know to succeed in the Canadian Healthcare Technology environment.
// H ow to work effectively with your biggest customers: governments. // Stakeholder and government advocacy to support your regulatory, reimbursement and policy objectives. // Examples of how to implement an effective product life-cycle strategy in the evolving regulatory environment.
// S ubmissions to the CDR: What they need to see to give you the ‘Yes’. // How you can effectively manage your mainstream and biologics submissions to develop a consistent and credible plan which will enhance long-term relationships with the CDR. // How you can overcome the challenges and meet the gold standard.
Bill Dempster Director, Health & Pharma, Global Public Affairs WORKSHOP
reparing for a negotiated P agreement: ensuring a profitable outcome
// W hen should you start and who should you speak to? How to ensure your marketing is aligning the messages agreed upon in Market Access negotiations. // One goal - one strategy - one message: Best practice in setting up your launch team to effectively optimize market access knowledge. // Learn the importance of how feedback from the field force can produce an effective internal cycle of information to further improve approval processes.
Scott Gavura Director, Provincial Drug
Rx&D
Lesia Babiak Vice-Chair, Federal Policy, Johnson & Johnson
The Provincial Challenge: Examine real challenges and opportunities when getting your drug approved in the provinces and learn the crucial do’s and don’ts when in negotiations
Strategies you need to implement to get the best probability of national coverage for your drug // E stablish where the future funding and control will lie: PMPRB or Provincial authority and what this will mean for the price of your drug. // Discover strategies which dictate the provincial thinking when discussing your reimbursement. // Develop best-practice methods in listing negotiations and how value can lead to success in pricing.
// T he methods you need to know when presenting drug safety, costeffectiveness and pricing agreements between each province and what the major barriers are that you will face. // Discover what priority the provinces give for approval and what added value you need to show to win them over. // Establish a clear plan that ensures you continue to improve on dialogue and relationships to develop a win-win situation in the provinces.
Doug Grant, Vice President, Corporate Affairs, Bayer
New ways in creating value through the measurement of real world drug safety and effectiveness (RWDSE)
PA N E L D I S C U SS I O N
CALL
+1 866 996 1235
FAX
+1 800 814 3460
EMAIL [email protected] ONLINE www.eyeforpharma.com/MACanada
Expanded access using Named Patient Programs: Named Patient Programs to speed pre-launch market access
// A nalyze the current negotiated agreement environment and impacts on stakeholders. // Are negotiated agreements a fad or trend? // Looking forward: is the future for negotiated agreements sustainable?
David Shum Director Reimbursement, Health Economics Roche
Wyatt Health.
Associate Principal. ZS Associates
& Pricing Practice Lead, ZS Associates
How you should plan and implement negotiated agreements for drugs in today’s market
PA N E L D I S C U SS I O N
Private payers in the Canadian Market. What are the future challenges and opportunities.
What should marketers know about payers, market access and risk sharing?
Ed Schoonveld Principal, Market Access
Bristol Myers Squibb
// P ayers have always said that they will pay for drugs that are effective in the real world, but how do you prove effectiveness in the real world? // What perspectives and elements do you need to consider when measuring real world drug safety and effectiveness? // Learn a practical approach to measuring effectiveness that will validate desired outcomes and give payers the confidence they need to reimburse your drug.
Anna Braeken Head of General Medicine, Bayer
// O verview of global payer environment and latest trends. // How should market access impact the marketing process and clinical research? // How do you craft a value story that is compelling to payers? // What exactly is risk sharing and who is actually sharing?
Krista Scaldwell VP Market Access,
George Wyatt Managing Director,
Adam Siskind
TO REGISTER
Strategies you need to know in the product launch phase
// A n update on the New Drug Funding Program, with highlights of treatment patterns and program forecasts. // A description of CCO’s data analysis and reporting framework for systemic treatment data. // Why you should incorporate this framework to help you align best practice with public reimbursement.
Normand Laberge Vice-President,
4 EASY WAYS
ession D: Market Access S with Commercial Divisions
Use systemic treatment data to improve outcomes for patients
// H ear a descriptive and comparative analysis of the Canadian market from an IP, Pricing and reimbursement aspect and how this impacts on your geographic strategy. // Establish where the future funding and control lies, with the PMPRB or Provincial authorities? // Develop best-practice in listing negotiations and understand how transparency and value can lead to greater success in pricing.
Three Simple Steps to Register Now!
// L earn the role of Named Patient Programs and expanded access programs, what they are and why they exist. // Understand the Special Access Program of Health Canada from a pharma perspective including legal, regulatory and compliance requirements. // Review best in class recommendations and internal resource requirements to effectively manage and execute named patient programs.
Neelima Firth Director, The Aequitas Group
Visit www.eyeforpharma.com/macanada for more information
FOR PHARMA & BIOTECH COMPANIES 2 Day Conference Pass, Full event recording, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
// W hat are the main changes to the PMPRB’s 1994 Excessive Pricing Guidelines? // What are the implications of the new Guidelines? // What can be expected in the future and what measures should be taken.
2 Day Conference Pass, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
FOR SOLUTION PROVIDERS & CONSULTANTS
Patented Medicine Prices Review Board
CDN $1999
CDN $1499
CDN $1799
EARLY BIRD PRICE
(Save CDN $300 - Register by September 18th, 2009)
2 Day Conference Pass, Full event recording, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
// D iscover how to manage PMPRB scrutiny whilst developing competitive prices in the market. // Identify what market forces are proving major barriers in sustaining long-term pricing i.e Generics, Public Opinion, how you can manage these to lower the impact on your drug. // Understand what the new excessive price guidelines released this summer will mean for your products.
STANDARD PRICE
CDN $1799
CDN $2099
CDN $1599
CDN $1899
Silver Pass 2 Day Conference Pass, Workshops, Roundtables, Lunch, Access to pre-event and post event networking.
NGOs And Regulatory Bodies Pass
CDN $699
2 Day Conference Pass, Full event recording, Access to all workshops, Access to all roundtables, Lunch, Access to pre-event and post event networking.
Martin Mason Partner, Gowlings Legal
Canadian pharmaceutical pricing – where do we go from here?
CDN $400
Full event recording
// N ew PMPRB Guidelines – examine the day to day impact on Canadian pricing practice. // How does Canada fare in the global context of competitive pricing? // Looking ahead – is there a formula for success?
Mr/Mrs/Ms/Dr:
First name:
Last name:
Company:
Position/Title:
Telephone:
Fax:
Email:
Claudia Neuber Senior Pricing Manager,
Address:
AstraZeneca
// U nderstand the emerging role of the pharmacists as KOLs in the Market Access environments. // How can innovatives move away from ‘me-too’ drugs to show incremental value from the current formulary drug. // Establish new ways in creating clear and transparent safety of your drug.
CDN $1699
Gold Pass
Measuring the long-term impact of pricing regulations
Reality in 2010 and beyond
STANDARD PRICE
Silver Pass
Barbara Ouellett Executive Director,
PA N E L D I S C U SS I O N
EARLY BIRD PRICE
(Save CDN $300 - Register by September 18th, 2009)
Gold Pass
The Changing PMPRB landscape and the impact of the new Excessive Pricing Guidelines
Senior Level Pharma Speakers TBC
Strategies to succeed in a competitive market for public reimbursement
Or visit www.eyeforpharma.com/macanada to register instantly
ession E: Pricing S & Reimbursement - Key Strategies For Effective P&R Negotiations
I enclose a check/draft for: (Payable to First Conferences Ltd)
Please invoice my company:
Postcode:
Country:
Credit card number: Expiry date:
Security number:
Name on card:
Purchase Order Number: Please charge my credit card: Amex
Visa
Mastercard
Signature:
FAX THIS FORM BACK TO +1 800 814 3460 TERMS & CONDITIONS Places are transferable without any charge. Cancellations before October 9, 2009 incur an administrative charge of 25%. If you cancel your registration after October 9, 2009 we will be obliged to charge the full fee. Please note – you must notify eyeforpharma in writing of a cancellation, or we will be obliged to charge the full fee. The organisers reserve the right to make changes to the programme without notice. All prices displayed are exclusive of VAT unless otherwise stated but, VAT will be charged, where applicable, at the prevailing rate on the invoice date and the relevant details will appear on the invoice. NB: FULL PAYMENT MUST BE RECEIVED BEFORE THE EVENT
Dear Colleague... After many months speaking to senior-level pharma industry executives in Canada, the biggest challenge we’re facing right now is how to bring a drug to market effectively and efficiently in this challenging environment.
Researched & Organized by eyeforpharma
World Class Speakers at a Glance
This meeting will address the key challenges you face including payor, patient and KOL engagement, relationship building, pricing & reimbursement strategy, CDR plans, pricing & drug safety and internal access management.
Daaron Dohler
You will leave the summit with a case-study driven road map for success in Canadian market access landscape – guaranteed. I look forward to meeting you and your colleagues in Toronto.
Best regards,
Vice President, Rx&D
Barbra Ouellet
Executive Director, PMPRB
Jon Gwillim VP North America eyeforpharma
PS. Sign up early and save CDN $300!
Follow me on LinkedIn www.linkedin.com/in/JonathanGwillim Group Search: Market Access for Canadian Pharma
Add Value for Stakeholders to Achieve Effective Drug Approval
Doug Grant
Vice President, Bayer
Anna Braeken
// Market Access
Vice President
// Health Economics
Director Federal Affairs & Health Policy, Johnson & Johnson
// Federal Policy // CDR Policy
Martin Mason
// Provincial Policy
Vice President, BMS Partner, Gowlings Legal
// Regulatory Affairs
David Shum
// Commercial Management
Director Reimbursement & Health Economics, Roche
Scott Gavura
Director Provincial Drug Reimbursement Programs, Cancer Care Ontario
Principal, Market Access & Pricing Practice Lead, ZS Associates
Neelima Firth
Director, The Aequitas Group Supported by
eyeforpharma events never fail to deliver. Ian Talmage, VP Global Marketing, Bayer Healthcare
4 EASY WAYS TO REGISTER CALL
+1 866 996 1235
FAX
+1 800 814 3460
EMAIL [email protected] ONLINE www.eyeforpharma.com/MACanada
Visit www.eyeforpharma.com/MACanada
36O
PM
THE FULL SPECTRUM OF PRODUCT MANAGEMENT
Reasons to Attend
// 8 Presentations From VPs // 18 Senior Level Speakers // 12+ Hours Worth of Networking // The Premier Meeting Place for Pharma & Regulators in Canada
CDR
Barbara Ouellet PMPRB
SAVE CDN $300
Add Value for Stakeholders to Achieve Effective Drug Approval
book before 18th September
Krista Scaldwell
Ed Schoonveld
SPEAKER FACULTY: Vice President
Lesia Babiak
Gerogre Wyatt
Canada
Two Day Conference November 10–11, 2009 Radisson Admiral, Toronto, Ontario
The event will attract VPs, heads, directors and managers of: // Pricing & Reimbursement
Senior Pricing Manager, AstraZeneca
Market Access
Who Should Attend?
Head General Medicine, Bayer
Claudia Neuber
Researched & Organized by eyeforpharma
Brian O’Rourke
President & General Manager, Takeda Canada, Inc
Managing Director, Wyatt Health
Two Day Conference November 10–11, 2009 Radisson Admiral, Toronto, Ontario
Canada
Normand Laberge
We will bring together pharma industry thoughtleaders from Bayer, Abbott, BMS, Takeda, J&J and teamed them up with CDR, PMPRB and Cancer Care Ontario as well as many other key stakeholders to provide you with a platform for learning, debate and networking.
Market Access
Vice President, CDR
9 Big Pharma speakers reveal their strategies and top tips
Pharma
Pharma
Brian O’Rourke
This is your invitation to attend an innovative summit that will address the most pressing issues unique to the Canadian pharma industry.
Hear from experts on the changing governmental and provincial landscape and learn how to get the most out of your relationship on a federal level.
9 Big Pharma speakers reveal their strategies and top tips
Experts Will Discuss: // The Impact Of PMPRB On Pharma In 2010 // Effective Internal Market Access Management
Real Case Studies from 6 VPs
President and General Manager
Takeda Canada, Inc
Doug Grant Vice President Corporate Affairs
Bayer
Krista Scaldwell Vice President Market Access
BMS
Lesia Babiak Director, Federal Policy
Janssen-Ortho
eyeforpharma always deliver cutting-edge, concise conferences on a global scale, I am proud to be associated with them and see them as a key player in delivering up-to-date intelligence to the industry. Len Starnes, Head Of Digital Marketing & Sales, Bayer Schering
For the latest information visit www.eyeforpharma.com/MACanada Global Sponsor
Join eyefoprharma’s Market Access Canada LinkedIn group to be kept updated and to open up your network to the key players in the space. Search for ‘Market Access Canada’ in the Group directory.
// Better CDR Engagement // Best Practice Pricing & Reimbursement Case Studies // Federal & Provincial Government Communication
Daaron Dohler
Gold Sponsor
Supporting Sponsor
Related Documents
Market Access Canada
June 2020 7
Market Access
August 2019 33
03 Market Access Appendix 3
December 2019 17
Market Access Providers Limited_january 2009
May 2020 6
User Guide Market Access Map
November 2019 10